NEWS RELEASE

Now ideas for wellness
meiji

Meiji Seika Pharma Co., Ltd.

January 29, 2025

Safinamide, a Parkinson's Disease Treatment Sublicensed to Zambon, Approved in China

Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, "Meiji") announced that safinamide (INN, product name in China: XADAGO®), a Parkinson's disease treatment sublicensed in China to Zambon S.p.A. (headquartered in Milan, Italy, "Zambon"), has been approved by the National Medical Products Administration (NMPA) in China. The product is set to launch in the second quarter of 2025 and will be marketed by a Zambon's Chinese subsidiary.

Safinamide, discovered and developed by Newron Pharmaceuticals S.p.A. (headquartered in Milan, Italy, "Newron"), is a key option for patients with Parkinson's disease with its dual mechanism of action, dopaminergic (reversible MAO-B inhibition) and non-dopaminergic (glutamate modulation), that makes it a valuable treatment for symptoms' control.

In 2011, Meiji and Newron entered into a licensing agreement, granting exclusive rights to research, develop, manufacture, and commercialize safinamide in Japan and in key Asian territories. In 2017, Meiji sublicensed to Eisai Co., Ltd. (headquartered in Tokyo, Japan) exclusive rights for marketing of safinamide in Japan, as well as for the development and marketing of safinamide in 14 countries/regions in Asia, excluding China. In the same year, Meiji sublicensed exclusive rights to research, develop, manufacture, commercialize and import safinamide in China (excluding Hong-Kong and Macao) to Zambon.

Meiji sincerely hopes that safinamide will be of great benefit to patients suffering from Parkinson's disease in China and throughout Asia.